These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8134734)

  • 1. Cross-validation in survival analysis.
    Verweij PJ; Van Houwelingen HC
    Stat Med; 1993 Dec; 12(24):2305-14. PubMed ID: 8134734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
    Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB
    Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy fails to improve survival in advanced ovarian cancer: but is it the real culprit?
    Di Giorgio A; Sammartino P; Biacchi D
    Int J Gynecol Cancer; 2011 May; 21(4):596. PubMed ID: 21543925
    [No Abstract]   [Full Text] [Related]  

  • 4. Time-dependent effects of fixed covariates in Cox regression.
    Verweij PJ; van Houwelingen HC
    Biometrics; 1995 Dec; 51(4):1550-6. PubMed ID: 8589239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penalized likelihood in Cox regression.
    Verweij PJ; Van Houwelingen HC
    Stat Med; 1994 Dec 15-30; 13(23-24):2427-36. PubMed ID: 7701144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990.
    Venesmaa P
    Obstet Gynecol; 1994 Jul; 84(1):8-11. PubMed ID: 8008329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies of prognostic factor and chemotherapeutic effect of epithelial ovarian cancer using Cox's proportional hazard model].
    Umesaki N; Sugawa T; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2351-6. PubMed ID: 8259850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patients with advanced ovarian cancer after negative second-look laparoscopy--follow up study].
    Pudełek J; Kojs Z; Urbański K; Mituś J; Reinfuss M; Klimek M
    Ginekol Pol; 2004 Feb; 75(2):85-90. PubMed ID: 15108578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas.
    Raspollini MR; Amunni G; Villanucci A; Baroni G; Boddi V; Taddei GL
    J Chemother; 2003 Aug; 15(4):380-6. PubMed ID: 12962367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy.
    Lassmann S; Shen Y; Jütting U; Wiehle P; Walch A; Gitsch G; Hasenburg A; Werner M
    Clin Cancer Res; 2007 Jul; 13(14):4083-91. PubMed ID: 17634533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
    Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
    Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.
    Kiselev VI; Ashrafyan LA; Muyzhnek EL; Gerfanova EV; Antonova IB; Aleshikova OI; Sarkar FH
    BMC Cancer; 2018 Sep; 18(1):904. PubMed ID: 30236079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of long-term survival: use of diagnostics and robust estimators with Cox's proportional hazards model.
    Valsecchi MG; Silvestri D; Sasieni P
    Stat Med; 1996 Dec; 15(24):2763-80. PubMed ID: 8981685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
    van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
    Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.